Thomas Lynch co-opted to the Board of Tripep

The former Vice Chairman and CFO of Elan Corporation Thomas Lynch has accepted an offer to join the Board of Tripep. Mr. Lynch also participated in the recently completed Tripep private placement. The Board of Directors of Tripep has resolved to accept the recommendation of the nomination committee that Thomas Lynch be co-opted as Director of the Board with immediate effect. The nomination committee proposes that Thomas Lynch be elected as a full member of the Board at the next Annual General Meeting in April of 2005. Mr. Lynch worked in a variety of capacities in Europe’s largest biotech company, Elan Corporation Plc, from 1993 to 2004. From the position as chief financial officer and executive vice-president; and subsequently as vice-chairman Mr. Lynch led Elan’s transformation from a drug delivery company to a biotechnology company through a series of corporate and product acquisitions and joint ventures. Between 2002 and 2004, Mr. Lynch developed and then participated in the implementation of Elan’s recovery plan, including the resolution of related regulatory and litigation issues. In 1994, Mr. Lynch founded a company which became Warner Chilcott, Plc (having negotiated and financed the acquisition of the Warner Chilcott division from the Warner-Lambert Company in 1996.) Mr. Lynch was a board member of that company from 1994 through 1999 and from then until 2002 as a director of Galen Plc, which acquired Warner Chilcott in 1999. Thomas Lynch is the non-executive chairman and major shareholder of Amarin Corporation Plc, an emerging biotech specialty pharmaceutical company, specialising in neurological diseases. Amarin has just completed a major acquisition and financing round to enable it to undertake the pivotal clinical trials and establish sales and marketing infrastructure. In addition to membership of the board of the Royal Opera House in London, Mr. Lynch is a member of the International Committee of the Kennedy Center, Washington D.C. He also serves as a member of the board of Queen’s University of Belfast Foundation and is an advisor to Somerville College, University of Oxford, England. “I am very pleased that Mr. Lynch has agreed to join the Board of Tripep and invest in the Company. He brings an enormous wealth of experience from the Biotech Industry to Tripep. Moreover, his broad international network will be invaluable to the Company as it prepares to enter its phase I/II clinical trials on the anti-HIV candidate drug alphaHGA and in initiating discussions with commercial partners. Mr Jan Nilsson’s recent appointment as CEO as well as the appointments of Professor William Hall and Professor Yiming Shao as Directors of the Board; and the completion of the recent fundraising are all factors that strongly positions Tripep to meet the new challenges that the company is facing in connection with the Phase I/II trials that are scheduled to commence early next year”, says Mr. Rolf L. Nordström, Chairman of the Board. For more information, please contact: Rolf L. Nordström, Chairman, Tripep AB Tel: +44 20 7839 8686, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@labmed.ki.se